Esperion Therapeutics Inc (ESPR), Intercept Pharmaceuticals Inc (ICPT): Visium and OrbiMed’s Recent Activity in Biotech
Stocks in the biotechnology industry have been very active as of late, with companies' shares registering significant gains.
Posts Tagged ‘Orbimed Advisors’
Healthcare Hedge Fund Orbimed’s Top Picks and New Move
According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals...
Sientra Inc (SIEN), TESARO Inc (TSRO) and Clovis Oncology Inc (CLVS): Orbimed’s Top New Picks
Samuel Islay's Orbimed Advisors has revealed its equity portfolio as of end of 2014, in a recent filing with the Securities and Exchange Commission.
Illumina, Inc., Walgreens Boots Alliance Inc, Valeant Pharmaceuticals Intl Inc: Billionaire Halvorsen’s Top 3 Picks
Andreas Halvorsen’s Viking Global disclosed its top three picks for the past quarter in a 13F Form filed with the U.S. Securities and Exchange Commission.
Shire PLC (ADR), Allergan, Inc., Time Warner Cable Inc: John Paulson’s Top Merger Picks
John Paulson's Paulson & Co has been having it rough for the past two years, as far as stock picking goes.
Ascendis Pharma A/S (ASND): Orbimed Advisors Takes Activist Stake in Newly Public Company
Samuel Isaly’s Orbimed Advisors has taken an activist stake in the recently listed Ascendis Pharma A/S (NASDAQ:ASND), an early-stage drug company working on a novel method of...
Mirati Therapeutics Inc. (MRTX): Baker Bros. Advisors Increases Stake in Growing Stock
Julian Baker and Felix Baker’s Baker Bros. Advisors recently disclosed an increase of around 929,700 shares to its position in Mirati Therapeutics, Inc. (NASDAQ:MRTX).
Zeltiq Aesthetics Inc (ZLTQ), Five Prime Therapeutics Inc (FPRX): Point72’s Latest Bullish Moves
Steve Cohen’s Point72 Asset Management has made bullish moves into a pair of medical technology stocks.
Arrowhead Research Corp (ARWR): Bridger Management Builds 5.5% Passive Stake
Roberto Mignone’s Bridger Management has amassed a 5.5% stake in Arrowhead Research Corp (NASDAQ:ARWR) according to a 13G filing with the Securities and Exchange Commission ...
Viking Global Trims Position in Illumina Inc (ILMN) But Might Still Be Bullish
According to its latest 13G filing, Andreas Halvorsen’s Viking Global reduced its stake in Illumina Inc (NASDAQ:ILMN) by 461,100 shares.
Sientra Inc (SIEN): Orbimed Discloses Major Stake in Newly Public Company
Samuel Isaly's healthcare-focused fund Orbimed Advisors has disclosed a new position in Sientra Inc (NASDAQ:SIEN), a company that just has gone public.
Arrowhead Research Corp (ARWR), ValueVision Media Inc (VVTV): QVT Financial and Cannell Capital Disclose Their Latest Moves
In two recent filings with the Securities and Exchange Commission, Daniel Gold's QVT Financial and J.
VIRGINIA NATL BNK (VABK), Alimera Sciences Inc (ALIM), Advanced Photonix, Inc. (API): Hedge Funds Disclose Moves In Their Equity Portfolios
Tim Mullen and his fund, Swift Run Capital Management, have sent a presentation to the management of VIRGINIA NATL BNK (OTCMKTS:VABK), in which they have outlined potential ...
Altisource Asset Management Corp (AAMC), Affimed Therapeutics BV (AFMD): Orbimed Advisors and Luxor Capital Group Are Bullish on These Companies
Altisource Asset Management Corp (NYSEMKT:AAMC) and Affimed Therapeutics BV (NASDAQ:AFMD) felt hedge funds’ bullishness lately.
Relypsa Inc (RLYP): Orbimed Advisors Trims Its Exposure to the Company
As a new filing with the Securities and Exchange Commission showed today, Samuel Isaly's Orbimed Advisors have trimmed its exposure to Relypsa Inc (NASDAQ:RLYP).
Charter Communications, Inc. (CHTR), Intuitive Surgical, Inc. (ISRG), Barrick Gold Corporation (USA) (ABX): Slate Path Capital Top Three Picks
Slate Path Capital, managed by David Greenspan, recently filed its 13F with the U.S. Securities and Exchange Commission.
InterMune Inc (ITMN), United Therapeutics Corporation (UTHR), Cyberonics Inc. (CYBX): Palo Alto Investors Loves Healthcare Stocks
Palo Alto Investors is a hedge fund founded by William Leland Edwards in 1989, and managed by him ever since.
Intercept Pharmaceuticals Inc. (ICPT), Bristol-Myers Squibb Co (BMY), Biogen Idec Inc (BIIB): Orbimed Advisors Top Stocks in Q2
Orbimed Advisors, led by Samuel Isaly, recently published its 13F filing with the U.S. Securities and Exchange Commission.
Orbimed Advisors Further Cuts Exposure To Intercept Pharmaceuticals Inc. (ICPT)
Orbimed Advisors, led by Samuel Isaly, has disclosed cutting its position in Intercept Pharmaceuticals Inc. (NASDAQ:ICPT).
Walgreen Company (WAG), llumina Inc. (ILMN), Valeant Pharmaceuticals Intl Inc (VRX): Billionaire Andreas Halvorsen’s Top Stock Picks
Andreas Halvorsen’s Viking Global recently disclosed its long equity positions for the second quarter of 2014. The fund declared holdings worth more than $22.9 billion.
Cognizant Technology Solutions Corp (CTSH), Titan International Inc. (TWI), Salix Pharmaceuticals Ltd. (SLXP) Among Stocks Hedge Funds Are Bullish On
Amidst the 13F filing season, several hedge funds have also been filing Schedule 13G forms, disclosing changes that took place after June 30, 2014, in their equity positions.
Loxo Oncology Inc (LOXO): Deerfield Management Discloses 13.65% Activist Stake
Samuel Isaly's Orbimed Advisors has disclosed holding a stake in Loxo Oncology Inc (NASDAQ:LOXO).
Deepak Gulati’s Argentiere Capital’s Top Stock Picks
Zug, Switzerland-based Argentiere Capital is an alternative investment management firm, which was founded by Deepak Gulati. Mr.
Bill Ackman’s Pershing Square Settles Litigation With Allergan Inc. (AGN)
Pershing Square, managed by Bill Ackman, revealed in a new filing with the U.S. Securities and Exchange Commission that it has settled a lawsuit with Allergan Inc. (NYSE:AGN).
Triumph Group Inc (TGI), Intercept Pharmaceuticals Inc (ICPT), Zynga Inc (ZNGA): Viking Global’s Top 5 Small-Cap Picks
Small-cap picks from individual funds might provide investors with attractive investment options.
Pine River Capital Management’s Top Bullish Moves During the First Quarter
A few days ago, Brian Taylor’s Pine River Capital Management, disclosed its equity positions at the U.S. Securities and Exchange Commission.
Orbimed Advisors Cuts Stake In Intercept Pharmaceuticals Inc (ICPT)
Orbimed Advisors is limiting exposure to Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after selling approximately 81,305 shares in one transaction at $320 a piece, according...
Sabby Management Adds Bioline RX Ltd (BLRX) & Recro Pharma Inc (REPH) to Its Equity Portfolio
In a couple of new filings with the SEC, Hal Mintz's Sabby Management disclosed adding two companies to its equity portfolio: Bioline RX Ltd (NASDAQ:BLRX) and Recro Pharma Inc...
Viking Global Boosts Its Stake in Illumina, Inc. (ILMN)
According to a new filing with the Securities and Exchange Commission, Andreas Halvorsen’s fund Viking Global, has upped its position in Illumina, Inc.
Broadfin Capital Initiates Stake in Pernix Therapeutics (PTX)
Last night, Broadfin Capital, a healthcare focused hedge fund managed by Kevin Kotler, disclosed in a Securities and Exchange Commission filing that it has initiated a 3.5 million...
Samuel Isaly Says He Is Fond of Regeneron Pharmaceuticals Inc (REGN) & InterMune Inc (ITMN)
Samuel Isaly's Orbimed Advisors is one of the largest hedge funds focused almost entirely on the healthcare sector. In a recent intervention on CNBC, Mr.
Sanofi-Aventis Purchases $42.4 Million Worth of Regeneron Pharmaceuticals Inc (REGN)’s Stock
On Jan. 29th, Sanofi-Aventis, a European pharmaceutical group and Large Shareholder at Regeneron Pharmaceuticals Inc (NASDAQ:REGN), filed a Form 4 report at the U.S.
Tang Capital Management Discloses Moves into La Jolla Pharmaceutical Company (LJPCD), Vanda Pharmaceuticals Inc. (VNDA), Mirati Therapeutics Inc. (MRTX) & Others
Tang Capital Management, led by Kevin C. Tang, revealed in a filing several moves that have impacted its equity portfolio.
Visium Asset Management Ups Stake in Skyrocketing Intercept Pharmaceuticals Inc (ICPT)
Jacob Gottlieb's Visium Asset Management has increased its stake in Intercept Pharmaceuticals Inc (NASDAQ:ICPT), according to an amended filing with the SEC. Gottlieb's fund...
Orbimed Advisors Discloses 33.5% stake in Relypsa Inc (RLYP)
Sam Isaly’s Orbimed Advisors disclosed holding a 33.5% stake in Relypsa Inc (NASDAQ:RLYP), a company which recently conducted its Initial Public Offering.
Samuel Isaly, Orbimed Advisors Disclose Position in Post-IPO Relypsa
Sam Isaly’s Orbimed Advisors disclosed its position in Relypsa Inc (NASDAQ:RLYP), a company that recently conducted its IPO.
Samuel Isaly, Orbimed Advisors Lower Position in NxStage Medical
Samuel Isaly's hedge fund, Orbimed Advisors, decreased its stake in NxStage Medical, Inc. (NASDAQ:NXTM) to around 2.89 million shares, from 3.14 million held earlier.
Peter Kolchinsky’s RA Capital Has Been Very Active This Month
Since the beginning of November, Peter Kolchinsky's RA Capital Management has informed the U.S.
Orbimed Follows Baker Bros and Buys Some Mirati Therapeutics Shares
Orbimed Advisors, a fund focused on the healthcare sector, led by Samuel Isaly, disclosed minutes ago purchasing 125,000 shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX).
Samuel Isaly’s Orbimed Advisors Sells Some Intercept Pharmaceuticals Stock at $62.50/Share
Orbimed Advisors, Intercept Pharmaceuticals: Samuel Isaly and his hedge fund, Orbimed Advisors, is focused on healthcare stocks.
Orbimed Downgrades its Position in Intercept Pharmaceuticals
Orbimed Advisors, Intercept Pharmaceuticals: In a recent SEC filing, Samuel Isaly and his hedge fund, Orbimed Advisors, reported decreasing their holding in Intercept Pharmaceuticals...
Should You Buy Fluidigm Corporation (FLDM)?
Now, according to many market players, hedge funds are assumed to be overrated, old investment vehicles of an era lost to time.
Is Pacira Pharmaceuticals Inc (PCRX) Going to Burn These Hedge Funds?
To the average investor, there are many methods market participants can use to analyze publicly traded companies.
Hedge Funds Are Crazy About Astex Pharmaceuticals, Inc. (ASTX)
In the 21st century investor’s toolkit, there are dozens of indicators shareholders can use to analyze publicly traded companies.
Should You Avoid Insulet Corporation (PODD)?
To many of your peers, hedge funds are assumed to be delayed, outdated financial tools of a period lost to current times.
Do Hedge Funds and Insiders Love Seattle Genetics, Inc. (SGEN)?
At the moment, there are a multitude of metrics shareholders can use to monitor stocks. A pair of the most useful are hedge fund and insider trading sentiment.
Hedge Funds Aren’t Crazy About Vocera Communications Inc (VCRA) Anymore
In today’s marketplace, there are a multitude of gauges shareholders can use to monitor their holdings.
Hedge Fund Bets On Onyx Pharmaceuticals, Inc. (ONXX)
As fast as we can type this, Phill Gross and Robert Atchinson's hedge fund, Adage Capital Partners, disclosed ownership of about 3.7 million shares of Onyx Pharmaceuticals, ...
Here is What Hedge Funds Think About Dynavax Technologies Corporation (DVAX)
If you were to ask many market players, hedge funds are seen as useless, outdated financial vehicles of a forgotten age.
Hedge Funds Are Dumping Dendreon Corporation (DNDN)
To the average investor, there are tons of methods shareholders can use to monitor the equity markets.
